



**Scientific Committee on Consumer Safety**

**SCCS**

**OPINION ON**

**hair dye *Indigofera tinctoria* (C170)  
CAS 84775-63-3**

**Submission III**



The SCCS adopted this document  
by written procedure on 10 January 2020

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

## **ACKNOWLEDGMENTS**

Members of the Working Group are acknowledged for their valuable contribution to this Opinion. The members of the Working Group are:

### SCCS members

Dr U. Bernauer  
Dr L. Bodin  
Prof. Q. Chaudhry (SCCS Chair)  
Prof. P.J. Coenraads (SCCS Vice-Chair and Chairperson of the WG)  
Prof. M. Dusinska  
Dr J. Ezendam  
Dr E. Gaffet  
Prof. C. L. Galli  
Dr B. Granum (Rapporteur)  
Prof. E. Panteri  
Prof. V. Rogiers (SCCS Vice-Chair)  
Dr Ch. Rousselle  
Dr M. Stepnik  
Prof. T. Vanhaecke  
Dr S. Wijnhoven

### SCCS external experts

Dr A. Koutsodimou  
Dr A. Simonnard  
Prof. W. Uter

All Declarations of Working Group members are available on the following webpage:  
[http://ec.europa.eu/health/scientific\\_committees/experts/declarations/sccs\\_en.htm](http://ec.europa.eu/health/scientific_committees/experts/declarations/sccs_en.htm)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

## 1. ABSTRACT

### The SCCS concludes the following:

(1) *In light of the data provided, does the SCCS consider Indigofera tinctoria (C170) safe when used in non-oxidative conditions hair colouring products at on-head concentrations of up to 25%?*

In light of the data provided, the SCCS considers that *Indigofera tinctoria* is safe when used in non-oxidative condition hair colouring products as on-head concentrations of up to 25%.

(2) *Does the SCCS have any further scientific concerns with regard to the use of Indigofera tinctoria (C170) in cosmetic products?*

A weak skin sensitisation potential cannot be excluded for *Indigofera tinctoria*.

Keywords: SCCS, scientific opinion, 1 *Indigofera tinctoria*, C170, hair dye, Regulation 1223/2009, CAS 84775-63-3, EC 283-892-6

Opinion to be cited as: SCCS (Scientific Committee on Consumer Safety), Opinion on hair dye 1 *Indigofera tinctoria* (C170) - Submission III, preliminary version of 10 January 2020, SCCS/1615/20

1

2 **About the Scientific Committees**

3 Two independent non-food Scientific Committees provide the Commission with the scientific  
4 advice it needs when preparing policy and proposals relating to consumer safety, public  
5 health and the environment. The Committees also draw the Commission's attention to the  
6 new or emerging problems which may pose an actual or potential threat.

7 They are: the Scientific Committee on Consumer Safety (SCCS) and the Scientific  
8 Committee on Health, Environmental and Emerging Risks (SCHEER) and are made up of  
9 scientists appointed in their personal capacity.

10 In addition, the Commission relies upon the work of the European Food Safety Authority  
11 (EFSA), the European Medicines Agency (EMA), the European Centre for Disease prevention  
12 and Control (ECDC) and the European Chemicals Agency (ECHA).

13  
14 **SCCS**

15 The Committee shall provide Opinions on questions concerning all types of health and safety  
16 risks (notably chemical, biological, mechanical and other physical risks) of non-food  
17 consumer products (for example: cosmetic products and their ingredients, toys, textiles,  
18 clothing, personal care and household products such as detergents, etc.) and services (for  
19 example: tattooing, artificial sun tanning, etc.).

20  
21 **Scientific Committee members**

22 Ulrike Bernauer, Laurent Bodin, Qasim Chaudhry, Pieter Jan Coenraads, Maria Dusinska,  
23 Janine Ezendam, Eric Gaffet, Corrado Lodovico Galli, Berit Granum, Eirini Panteri, Vera  
24 Rogiers, Christophe Rousselle, Maciej Stepnik, Tamara Vanhaecke, Susan Wijnhoven

25  
26 **Contact**

27 European Commission  
28 Health and Food Safety  
29 Directorate C: Public Health, Country Knowledge, Crisis Management  
30 Unit C2 – Country Knowledge and Scientific Committees  
31 L-2920 Luxembourg  
32 [SANTE-C2-SCCS@ec.europa.eu](mailto:SANTE-C2-SCCS@ec.europa.eu)

33  
34 © European Union, 2020

35  
36 ISSN ISBN

37  
38 Doi: ND-

39  
40 The Opinions of the Scientific Committees present the views of the independent scientists  
41 who are members of the committees. They do not necessarily reflect the views of the  
42 European Commission. The Opinions are published by the European Commission in their  
43 original language only.

44  
45 [http://ec.europa.eu/health/scientific\\_committees/consumer\\_safety/index\\_en.htm](http://ec.europa.eu/health/scientific_committees/consumer_safety/index_en.htm)

46

---

1			
2	<b>TABLE OF CONTENTS</b>		
3			
4			
5	1.	ABSTRACT.....	3
6	2.	MANDATE FROM THE EUROPEAN COMMISSION.....	6
7	3.	OPINION .....	7
8	3.1	CHEMICAL AND PHYSICAL SPECIFICATIONS.....	7
9	3.1.1	Chemical identity.....	7
10	3.1.2	Physical form .....	8
11	3.1.3	Molecular weight .....	8
12	3.1.4	Purity, composition and substance codes.....	8
13	3.1.5	Impurities / accompanying contaminants .....	9
14	3.1.6	Solubility .....	13
15	3.1.7	Partition coefficient (Log P <sub>ow</sub> ) .....	15
16	3.1.8	Additional physical and chemical specifications.....	15
17	3.1.9	Homogeneity and Stability.....	15
18			
19	3.2	FUNCTION AND USES .....	17
20	3.3	TOXICOLOGICAL EVALUATION.....	17
21	3.3.1	Acute toxicity .....	17
22	3.3.2	Irritation and corrosivity .....	18
23	3.3.3	Skin sensitisation.....	21
24	3.3.4	Toxicokinetics .....	23
25	3.3.5	Repeated dose toxicity .....	23
26	3.3.6	Reproductive toxicity.....	24
27	3.3.7	Mutagenicity / genotoxicity .....	26
28	3.3.8	Carcinogenicity.....	31
29	3.3.9	Photo-induced toxicity .....	31
30	3.3.10	Human data .....	32
31	3.3.11	Special investigations.....	32
32	3.3.12	Safety evaluation (including calculation of the MOS) .....	32
33	3.3.13	Discussion .....	32
34			
35	4.	CONCLUSION.....	34
36	5.	MINORITY OPINION .....	34
37	6.	REFERENCES .....	35
38	7.	GLOSSARY TERMS .....	36
39	8.	LIST OF ABBREVIATIONS .....	36
40			
41			

---

1 **2. MANDATE FROM THE EUROPEAN COMMISSION**

2  
3 **Background**

4  
5 Submission I for *Indigofera tinctoria* (C170) (CAS 84775-63-3) was submitted in October  
6 2003.

7  
8 On the 23 April 2004, the Scientific Committee on Cosmetic Products and Non-Food  
9 Products intended for Consumers (SCCNFP) adopted, by written procedure, an opinion  
10 (SCCNFP/0790/04) according to which..."a complete safety dossier on *Indigofera tinctoria* is  
11 required".

12  
13 Following the Submission II (2006) the SCCS adopted an opinion (SCCS/1439/11) at its  
14 16th plenary meeting of 18 September 2012 on *Indigofera tinctoria* (C170) with the  
15 following conclusion:

16 *The SCCS is of the opinion that the safety of Indigofera tinctoria used as a hair dye at a*  
17 *maximum concentration on the head of 25% cannot be assessed due to incomplete*  
18 *information.*

19 *The safety of Indigo (CI 73 000) used as a colorant should be re-assessed.*

20  
21 Submission III on the hair dye *Indigofera tinctoria* (C170) was transmitted by Cosmetics  
22 Europe in November 2017.

23  
24 According to the applicant the current submission supports the safe use of *Indigofera*  
25 *tinctoria* in non-oxidative conditions hair colouring products at on-head concentrations of up  
26 to 25%.

27  
28  
29 **Terms of reference**

30  
31  
32 *(1) In light of the data provided, does the SCCS consider Indigofera tinctoria (C170) safe*  
33 *when used in non-oxidative conditions hair colouring products at on-head concentrations*  
34 *of up to 25%?*

35  
36  
37 *(2) Does the SCCS have any further scientific concerns with regard to the use of Indigofera*  
38 *tinctoria (C170) in cosmetic products?*

1  
2 **3. OPINION**  
3 After requests for new information from the SCCS, an amended Submission III was  
4 transmitted in April 2018 followed by a Submission IV in May 2019. These two submissions  
5 are referred to as Submission III in this Opinion.

### 6 **3.1 CHEMICAL AND PHYSICAL SPECIFICATIONS**

#### 8 **3.1.1 Chemical identity**

##### 10 **3.1.1.1 Primary name and/or INCI name**

11 Common name: *Indigofera tinctoria*

12 INCI:

13 *Indigofera tinctoria* leaf  
14 *Indigofera tinctoria* leaf powder  
15 *Indigofera tinctoria* leaf extract  
16 *Indigofera tinctoria* extract

17 COLIPA code: C170

##### 20 **3.1.1.2 Chemical names**

21 *Indigofera tinctoria*, dried and pulverised leaves of *Indigofera tinctoria* L.

##### 22 **3.1.1.3 Trade names and abbreviations**

23 HQ Indigo

##### 25 **3.1.1.4 CAS / EC number**




26 CAS: 84775-63-3

27 EC: 283-892-6

##### 29 **3.1.1.5 Structural formula**

30 Complex chemical mixture.

##### 31 **Major components:**

 <p style="text-align: center;">indican (1)</p>	 <p style="text-align: center;">indigo (2)</p>	 <p style="text-align: center;">indirubin (3)</p>
<p>IUPAC name: (2R,3S,4S,5R)-2-(hydroxymethyl)-6-(1H-indol-3-yloxy)oxane-3,4,5-triol Molecular formula: C<sub>14</sub>H<sub>17</sub>NO<sub>6</sub></p>	<p>IUPAC name: (2E)-2-(3-oxo-1H-indol-2-ylidene)-1H-indol-3-one Molecular formula: C<sub>16</sub>H<sub>10</sub>N<sub>2</sub>O<sub>2</sub></p>	<p>IUPAC name: (3E)-3-(3-oxo-1H-indol-2-ylidene)-1H-indol-2-one Molecular formula: C<sub>16</sub>H<sub>10</sub>N<sub>2</sub>O<sub>2</sub></p>

32 Ref: 1-3

33

**3.1.1.6 Empirical formula**

/

**3.1.2 Physical form**

Finely divided greenish dispersible powder.

Ref: 1

**3.1.3 Molecular weight**

M.W.:

Indican: 295.29 g/mol

Indigo; Indigotin: 262.26 g/mol

Indirubin: 262.26 g/mol

Ref: 1

**3.1.4 Purity, composition and substance codes**

The analytical study of *Indigofera tinctoria* (E213339 and E502657) was performed on four batches:

- E213339 batch SM/KS/24/8kGy/2

- E502657 batch INP 161038

- E502657 batch KAN/IN/25 KGY/1216/01

- E502657 batch KAN/IN/25 KGY/1216/03

Upon clarification sought by the SCCS, the Applicant stated that a complete analytical description of the test material E213339 is not available due to shortage of one batch (SM/KS/24/8kGy/2). However, the two batch codes of *Indigofera tinctoria* E502657 and E213339 correspond to the same raw material i.e. *Indigofera tinctoria* leaf powder originating from the same geographical area in south of India, cultivated and harvested in Tindivanam, in the Tamil Nadu area. The batches were prepared using the same process, as evidenced by similar contents of the tracer molecule Indican (3.40% versus 3.68-3.75%). The only difference between the two codes is the level of irradiation to avoid bacteria contamination where the codes E213339 and E502657 were irradiated at 8 and 25 kGy, respectively. This has no impact on the powder composition. For the sake of clarification, Indirubin is highly expected to be present at the same level in the batches from both codes E213339 and E502657. This is corroborated by the measurements done on many batches of *Indigofera tinctoria* where the level of Indirubin was always found in the same range as in the described batches.

Purity of the three major components (Indican, Indigo and Indirubin) was tested by a UPLC/DAD method using external standard calibration against commercial reference standards presented in the Tables below. Detection wavelengths were set at 190-700 nm (extract profile) and 288 nm (quantification).

Reference standards					
Molecule	CAS	Supplier	Product-batch	Aspect & color	Purity
Indican (Indoxyl $\beta$ -D-glucoside)	487-60-5 1328-73-0	Sigma	MKBW4665V	white powder	98 %
Indigo	482-89-3	edQm	Indigo CRS batch 1	blue purple powder	98.2%
Indirubin	479-41-4 906748-38-7	Sigma	116M4603V	Dark purple powder	98.4%



Content of the three major components (Indican, Indigo and Indirubin)				
	<i>Indigofera tinctoria</i> (E213339) Batch:	<i>Indigofera tinctoria</i> (E502657) Batches:		
	SM/KS/24/8kGy/2 (g/100g)	INP 161038 (g/100g)	KAN/IN/25 KGY/1216/01 (g/100g)	KAN/IN/25 KGY/1216/03 (g/100g)
<b>Indican</b>	3.4	3.69	3.68	3.75
<b>Indigo</b>	0.02	0.07	0.08	0.06
<b>Indirubin</b>		0.02	0.02	0.04

Analytical data on additional six different batches of the code E502657 are summarised in the Table below, which shows that irradiation at 25 kGy does not result in significant changes in Indican, Indirubin and Indigo contents when compared to the same non-irradiated batches.

Analytical data on individual batches												
Batch number	KAN/INCONTRO/1216/01		KAN/INCONTRO/1216/02		KAN/INCONTRO/1216/03		KAN/INCONTRO/1216/04		KAN/INCONTRO/1216/05		KAN/INCONTRO/1216/06	
	Non-irradiated	Irradiated (25 kGy)	Non-irradiated	Irradiated (25 kGy)	Non-irradiated	Irradiated (25 kGy)	Non-irradiated	Irradiated (25 kGy)	Non-irradiated	Irradiated (25 kGy)	Non-irradiated	Irradiated (25 kGy)
Indican (%)	3.9	3.7	4.0	3.7	4.1	3.8	4.1	3.9	4.1	3.9	4.1	3.9
Indigo (%)	0.065	0.080	0.067	0.057	0.073	0.057	0.068	0.057	0.068	0.057	0.070	0.057
Indirubin (%)	0.014	0.024	0.013	0.023	0.016	0.035	0.014	0.022	0.014	0.027	0.015	0.035
Enzyme activity*10 (UA/g)	Not available	11.29	Not available	6.99	Not available	6.92	Not available	10.03	Not available	7.62	Not available	8.28

Ref: 4-5

### SCCS comment on Submission III

The additional data on the analysis of six different batches of the code E502657 demonstrate that there is no significant batch-to-batch variation in the content of Indican, Indigo and Indirubin.

In the irradiated batches of the code E502657, the content of the Indican is reduced and the content of Indirubin is increased in relation to the non-irradiated ones, while Indigo is increased only in KAN/IN/25 KGY/1216/01, and decreased in the rest of the batches.


The composition analysis refers only to 4% of the components for the test material E213339 that was used in 67% of the studies conducted for submission III.

### 3.1.5 Impurities / accompanying contaminants

#### Submission III


##### UPLC-PDA analysis

Approximately 100 mg of the leaf powder (accurately weighed) were transferred in a 10 mL volumetric flask (sample content depending). Samples were dissolved in DMSO and make up to volume with the same solvent. Samples were magnetically stirred for 30 min at 700 rpm. The final concentration of the solution is 1 g/100 mL (10 mg/mL). All samples were filtered through a 0.2 µm membrane filter (Acrodisc GHP -Pall) prior to the UPLC-PDA analysis. The separation was achieved on an Acquity BEH Phenyl analytical column (particle size 1.7 µm). Wavelengths were set to 190-700 nm (extract profile) and 288 nm (quantification).



1 Indigofera tinctoria (E502657) batch INP 161038 – Characteristic chromatogram


2017\_04\_04 - 0-21-1 – KAN/IN/25KGY/1216/01\_Indigo\_Indirubin\_Indican.lcd



2 Indigofera tinctoria (E502657) batch KAN/IN/25 KGY/1216/01  
3 Characteristic chromatogram

3  
4

2017\_04\_04 - 0-21-3 – KAN/IN/25KGY/1216/03\_Indigo\_Indirubin\_Indican.lcd



5 Indigofera tinctoria (E502657) batch KAN/IN/25 KGY/1216/03  
6 Characteristic chromatogram

7

8 Chemical characterisation by IR and <sup>1</sup>H-NMR

9 Additionally, batches KAN/IN/25KGY/1216/01 and KAN/IN/25KGY/1216/03 were  
10 characterised analytically by IR and <sup>1</sup>H-NMR. The samples were prepared and analysed in  
11 Dimethylsulfoxide-d6 (DMSO-d6). The samples were not totally dissolved in DMSO-d6. The  
12 spectra were recorded on the soluble part of sample obtained after filtration. The chemical  
13 characterization is described in the Table below.

14 According to the Applicant, the main results of the four batches were similar and are  
15 presented in the Table below.

16  
17 Taking into account that the four batches of *Indigofera tinctoria* leaf powder originate from  
18 the same geographical area, that they are produced using the same production process,  
19 that their contents of the tracer molecules Indican and Indigo are comparable and that the  
20 IR spectra and the <sup>1</sup>H NMR spectra of these four batches are identical, the Applicant  
21 considers that the composition analysis can be read across these four analysed batches.  
22

1 In conclusion, the composition of the three batches that underwent extensive analytical  
 2 characterisation is considered to be fully representative of the composition of batch  
 3 E213339 SM/KS/24/8kGy/2 and of the material that will be used in hair-colouring products.  
 4

	<b>E213339</b>	<b>E502657</b>		
	<b>SM/KS/24 /8kGy/2</b>	<b>INP 161038</b>	<b>KAN/IN/25 KGY/1216</b>	
			<b>01</b>	<b>03</b>
<sup>1</sup> H NMR spectrometry	Similar <sup>1</sup> H NMR spectra			
IR Spectrometry	Similar IR spectra			
Mineral matter (%w/w)		13.4	11.9	12.3
Ashes (%w/w)		4.6	3.1	3.0
Lipids (%w/w)		6.8	8.0	6.8
Soluble sugars (%w/w)		19.6	21.8	22.5
Polyphenols (%w/w)		3.7	3.6	3.1
Loss on drying (%w/w)		4.1	5.3	5.5
Crude fiber (%w/w)		3.5	8.1	7.8
Indican (%w/w)	3.40	3.69	3.68	3.75
Indigo (%w/w)	0.02	0.07	0.08	0.06
Indirubin (%w/w)		0.02	0.02	0.04
Amino acids (free) (%w/w)		1.0	0.9	0.9
Total protein content (%w/w)		20.5	19.1	15.1
Fragrance allergens (µg/g)		<10		
Heavy metals		Analysis performed Please refer to analytical file		
Pesticides		Rotenoids < 100 ppm (Not detected) Other pesticides < 50 ppb		

5  
6  
7  
8  
9  
10

The heavy metal test was performed by ICP-MS. Micro-wave assisted acid digestion using nitric acid and hydrogen peroxide was used for sample preparation.

1

<b><i>Indigofera tinctoria</i> (E502657) batches*</b>			
	INP 161038 ( $\mu\text{g/g}$ )	KAN/IN/25 KGY/1216/01 ( $\mu\text{g/g}$ )	KAN/IN/25 KGY/1216/03 ( $\mu\text{g/g}$ )
Cr	3.1	1.1	1.1
Co	0.6	0.3	0.3
Ni	4.2	4.0	3.1
Cu	9.5	9.5	9.4
Zn	35.0	40.4	40.2
As	0.1	<0.1	<0.1
Se	0.1	<0.1	<0.1
Cd	<0.1	<0.1	<0.1
Sb	<1.0	<1.0	<1.0
Ba	109.3	87.0	86.0
Nd	0.9	0.4	0.4
Hg	<0.1	<0.1	<0.1
Pb	79.1	8.4	8.2

\* Contents of heavy metals are controlled by quality specifications for the industrial quality.

2  
34 **Protein matter:**

5 1D gel electrophoresis profiles of the three batches of *Indigofera tinctoria* (E502957) are  
6 comparable and highlight the presence of several protein bands between 6 and 188 kDa.  
7 The two main detected bands correspond to the following molecular weights: 14 and  
8 49 kDa.

9 Total protein matter and free amino-acids contents using ion exchange chromatography:

10 **Total protein matter:**

- 11 - E502657 batch INP 161038: 20.5 (% w/w)
- 12 - E502657 batch KAN/IN/25 KGY/1216/01 : 19.1 (% w/w)
- 13 - E502657 batch KAN/IN/25 KGY/1216/03 : 15.1 (% w/w)

14 **Free amino-acids:**

- 15 - E502657 batch INP 161038 : 1.0 (% w/w)
- 16 - E502657 batch KAN/IN/25 KGY/1216/01 : 0.9 (% w/w)
- 17 - E502657 batch KAN/IN/25 KGY/1216/03 : 0.9 (% w/w)

18

19 **Fragrance level**

20 Fragrance allergens level in the 3 batches: < 10  $\mu\text{g/g}$ .

21

22 **Pesticides content**

23 The determination of pesticides was performed by LC/MS/MS or GC/MS/MS on 3 batches of  
24 the code E502657. Each sample is prepared using a QuEChERS extraction before injection in  
25 the analytical system. The absence of pesticides was checked in each *Indigofera tinctoria*  
26 sample by an adduct corresponding to the limit of quantification.

27 In the 3 batches of the code E502657, the 316 tested pesticides content was:

- 28 - E502657 batch INP 161038 : < 0.05  $\mu\text{g/g}$
- 29 - E502657 batch KAN/IN/25 KGY/1216/01 : < 0.05  $\mu\text{g/g}$
- 30 - E502657 batch KAN/IN/25 KGY/1216/03 : < 0.05  $\mu\text{g/g}$

31

32 **Rotenoides (tephrosin, deguelin, rotenone, dehydrodeguelin)**

33 Rotenone, deguelin, tephrosin and dehydrodegeulin were measured by UPLC with UV  
34 detection at 270nm and were not found in any of the 3 batches of the code E502657 (INP  
35 161038, KAN/IN/25/KGY 1216/01 and KAN/IN/25/KGY 1216/03) with a limit of  
36 quantification at 100 mg/kg (100 ppm).

37

Ref: 1, 6

38

39

**SCCS comment on Submission III**

A number of unknown peaks appear in the UPLC-PDA chromatograms of leaf powder for E502657; while the runtime of the provided chromatograms is short (it should be at least 5x<sub>tR</sub> of the latest eluted main compound (~ 25 min)). The analysis should provide chemical characterisation and quantification of all major impurities based on the % area content calculated at  $\lambda_{\max}$  of each of the major components.

In all of the analysed batches, the amount of lead (Pb) and antimony (listed in Annex II, EC 1223/2009) are above the acceptable limits set to 2 and 0.1 mg/kg, respectively. Heavy metal impurities must be kept below the acceptable limits. For heavy metal impurities > trace levels, the valence state of the ion and the salt form should be provided.

Ref: 7

**3.1.6 Solubility**

The raw material is a finely divided greenish dispersible powder made of dried and crushed leaves of *Indigofera tinctoria* containing insoluble matter such as cellulose fibres. For this reason, *Indigofera tinctoria* is not soluble, but dispersible. The test samples are prepared extemporaneously by making a homogeneous suspension of powder in the different vehicles (water, dimethylformamide or DMSO). This homogeneous suspension was used in the safety tests.

Indigo is sparsely soluble in organic solvents. The solvent of choice for its extraction is the DMSO. DMF is also able to solubilise Indigo, but this solvent conducts to the leuco form of Indigo.

Ref: 1

Solubility results of code E213339, based on visual inspection:

**Table 1 – Results of the Solubility Test**

Vehicle Tested	Test item Concentration	Solubility Check	Comments
AOO	10%	Unstable suspension	Not OK
DMF	10%	Unstable suspension	Not OK
MEK	10%	Unstable suspension	Not OK
PG	10%	Unstable suspension	Not OK
DMSO	10%	Homogeneous suspension	OK
DMSO	25%	Homogeneous suspension	OK
DMSO	50%	Non-homogeneous paste	Not OK

Ref: 8

Quantification of Indican, Indigo and Indirubin under the safety tests conditions

Upon clarification sought by the SCCS, the Applicant analysed three safety tests conditions in one batch (E502657 batch KAN/IN/25KGY/1216/01). Indican, Indigo and Indirubin levels were measured at 5 and 180 minutes (3 h) after sample preparation, the latter time point corresponding to the duration of test systems exposure in mutagenicity and genotoxicity studies. The results are presented in the Table below.

**Safety tests conditions-% of Indican, Indigo and Indirubin**

<i>E502657 batch</i> <i>KAN/IN/25KGY/1216/01</i>		<i>Indican (%)</i>	<i>Indigo (%)</i>	<i>Indirubin (%)</i>
<i>Systemic toxicity test</i> <i>(water)_condition 1</i>	<i>5 min</i>	2.03	0.09	0.02
	<i>180 min</i>	0.07	0.21	0.04
<i>Micronucleus/mammalian</i> <i>mutation tests (DMF then</i> <i>dilution in water)_condition 2</i>	<i>5 min</i>	3.69	0.05	0.04
	<i>180 min</i>	1.11	0.46	0.03
<i>Ames test (DMF then dilution in</i> <i>water)_condition 3</i>	<i>5 min</i>	3.10	0.04	0.02
	<i>180 min</i>	0.91	0.44	0.02

The levels of Indican, Indigo and Indirubin in the cataplasm at 60 min, the application time on-head, were compared to the levels obtained under the different toxicological tests conditions at 180 min, the exposure duration in the mutagenicity/genotoxicity tests and results are presented in the Table below.

**Comparison of the levels of Indican, Indigo and Indirubin in cataplasm (at 60 min) versus the 3 toxicological tests conditions (at 180 min)**

	<i>Indican (%)</i>	<i>Indigo (%)</i>	<i>Indirubin (%)</i>
<i>Cataplasm (60 min)</i>	0.11	0.38	0.04
<i>Systemic toxicity test condition</i> <i>(180 min)_condition 1</i>	0.07	0.21	0.04
<i>Micronucleus test condition</i> <i>(180 min)_condition 2</i>	1.11	0.46	0.03
<i>Ames test condition (180 min)_</i> <i>condition 3</i>	0.91	0.44	0.02

Overall, Indican was less hydrolysed under conditions 2 and 3 i.e. in the presence of DMF compared to the cataplasm (1.11, 0.91 and 0.11%, respectively), however the levels of Indigo and Indirubin were overall similar. Under condition 1, Indican was hydrolysed similarly as in the cataplasm yielding comparable levels of Indigo and Indirubin. In conclusion, these results suggest that the toxicological test systems were exposed to comparable levels of Indigo and Indirubin present in the cataplasm i.e. under on-head use conditions.

In the absence of full-characterisation of the hydrolysis products of Indican, the comparison of the chromatograms of the cataplasm versus the condition 1 (i.e. systemic toxicity test) for instance show overlapping profiles, corroborating the fact that the compounds present in the cataplasm on-head were also evaluated in the toxicological tests.

In brief, it is the Applicant's view that, taken together, the results presented above support the hydrolysis of Indican in the aqueous media used in the toxicological tests conditions, whether the tested material had been pre-suspended in DMF, in hot or room temperature water, and that both Indigo and Indirubin were generated therein at similar levels to which the consumer would be exposed to under on-head use conditions.

**3.1.7 Partition coefficient (Log P<sub>ow</sub>)****3.1.8 Additional physical and chemical specifications**

Where relevant:

- organoleptic properties (colour, odour, taste if relevant)
- melting point
- boiling point
- flash point
- vapour pressure
- density
- viscosity
- pKa
- pH: pH determination of code E502657 was performed at 25°C of an aqueous solution at 25% w/w:
- INP 161 038, KAN/IN/25KGY/1216/01 and KAN/IN/25KGY/1216/03: pH = 7.1
- Refractive index
- UV/visible light absorption spectrum

**Storage conditions:** Ambient temperature (20°C) and shielded from humidity.

Particles size distribution was determined using Static Light Scattering particle sizing (SLS) method.

	Indigofera Tinctoria (E502657) batches		
	INP 161038	KAN/IN/25 KGY/1216/01	KAN/IN/25 KGY/1216/03
<b>Volume results</b>			
D50 (µm)	36.4	45.3	51.4
Distribution width (µm)	0.7 to 424.0	0.8 to 625.0	0.8 to 639
<b>Number results</b>			
D50 (µm)	1.2	1.4	1.4
Distribution width (µm)	0.6 to 45	0.7 to 53.5	0.7 to 57.3

Ref: 9

**SCCS comment Submission III**


The pH of the code E213339 was not provided for the 25% formulation. According to the applicant, this code is not available anymore and it is not possible to supply further analysis.

**3.1.9 Homogeneity and Stability****Submission III****Stability of Indican in *Indigofera tinctoria* Cataplasms****Test Substance:** *Indigofera tinctoria* (code E502657) and batches KAN/IN/25 KGY/1216/01 and KAN/IN/25 KGY/1216/03

**Method**

For the kinetics, 5 g of the batches were added to three different mixing bowls with 15 g of water at appropriate temperature (25, 50 and 100 °C). A uniform cataplasm was then obtained by mixing with a flat-ended spatula. At every time point, a weighed amount of the cataplasm was transferred to a 5 mL volumetric flask and dissolved in DMSO and sonicated for 5 min. At T5 minutes, the first sample was collected and dissolved in DMSO. Sample weights were chosen in the range of 12 to 22 mg/mL. All samples were filtered through a 0.2 µm membrane filter (GHP) prior to use.

**HPLC-UV:** gradient elution – external standard calibration against commercial reference standards, λ = 280 and 288 nm (quantification)



Indigofera Tinctoria (E502657) batch KAN/IN/25 KGY/1216/01

**Kinetics Data:**

**Indigofera Tinctoria (E502657) batches KAN/IN/25Kgf/1216/01 and KAN/IN/25Kgf/1216/03 – Data in %**

	Enzyme (UA/g)	g/100 mL of	Content in dry biomass	Room temperature (25±2°C)			50 °C			100 °C		
				Time in minutes								
				T0	T30	T60	T0	T30	T60	T0	T30	T60
KAN/IN/25Kgf/1216/01	11.29	Indican	3.93	0.495	0.097	0.031	0.249	0.053	0.028	0.064	0.025	0.020
		Indigo	0.07	0.047	0.106	0.193	0.050	0.114	0.216	0.057	0.112	0.168
		Indirubin	0.05	0.019	0.024	0.032	0.020	0.025	0.031	0.021	0.027	0.033
KAN/IN/25Kgf/1216/03	6.92	Indican	3.78	0.60	0.07	0.03	0.38	0.05	0.03	0.12	0.03	0.02
		Indigo	0.07	0.05	0.11	0.18	0.05	0.10	0.18	0.05	0.10	0.16
		Indirubin	0.04	0.02	0.02	0.03	0.02	0.02	0.03	0.02	0.02	0.03

**Conclusions**

Two batches of *Indigofera tinctoria* (E502657 batch KAN/IN/25KGY/1216/01 and E502657 batch KAN/IN/25KGY/1216/03) containing Indican at 3.93% and 3.78%, respectively, were analysed. Stability of Indican in an *Indigofera tinctoria* cataplasm was tested.

- Rate of conversion of Indican is very fast in aqueous medium ~ 84 to 87 % at T5 minutes.
- Significant conversion of Indican and formation of Indigo and Indirubin is achieved at T30 minutes itself.

- Significant conversion of Indican is seen at room temperature. Although it is observed that higher temperatures result in faster rates of change.

- The results suggest that Indican is immediately hydrolysed after the addition of water, whatever its temperature (RT, 50° or 100°C), though at a slower pace at RT. No significant differences were noted after 1 hour as the levels of the 3 markers (Indican, Indigo and Indirubin) were similar between the three conditions evaluated (i.e. at RT, 50°C and



100°C). Approximately 0.02-0.03% of Indican was left, with a slight increase in Indigo reaching approximately 0.2% at 1h, whatever the initial water temperature, the powder final temperature reaching RT shortly after mixing. Indirubin level remains practically the same as in the dry powder.

- These results are in agreement with the literature data. The low levels of Indigo and Indirubin after one hour are not surprising, as they are related to the complexity of the reactions in the leaf powder as well as the short kinetic of 1h (maximum application time under use conditions). According to the existing knowledge, one hour is not sufficient to allow the complete transformation of Indican into the coloured components Indigo and Indirubin. The Indigo plants used to dye the textiles are generally covered with water and left to macerate for at least 10, or more, usually 16-22 hours, until the hydrolysis of the Indican into Indoxyl is as complete as possible. Then Indoxyl will be oxidized to Indigo (Cardon, 2007). Thus, it is highly likely that the Indigo and Indirubin levels will increase over time if the analysis was performed 24 h later.

Ref: 1, 10

### SCCS comments Submission III

It is well known that both Indigo and Indirubin can be formed after hydrolysis of Indican (Indoxyl glucoside) to Indoxyl and further oxidation. According to the Applicant, a significant conversion of Indican and formation of Indigo is observed after 30 min in all the tested conditions (25, 50 and 100°C). A number of unknown peaks appear at the provided HPLC-UV chromatograms ( $\lambda=280$  nm) for *Indigofera tinctoria* code E502657 batch KAN/IN/25 KGY/1216/01, while Indigo and Indirubin are not well resolved so as to be accurately quantitated. However, the chromatograms of the cataplasm versus the conditions used for systemic toxicity studies show overlapping profiles, indicating that the compounds present in the cataplasm on-head were also evaluated in the toxicological tests.

## 3.2 FUNCTION AND USES

The ingredient *Indigofera tinctoria* is used in non-oxidative hair colouring products at a maximum on-head concentration of 25% (i.e. 100 g of *Indigofera tinctoria* mixed with 300 mL of hot water between 50°C and 100°C).

Ref: 1

## 3.3 TOXICOLOGICAL EVALUATION

### 3.3.1 Acute toxicity

#### 3.3.1.1 Acute oral toxicity

##### Submissions I and II

No data submitted.

##### Submission III

No acute oral toxicity study was performed with *Indigofera tinctoria*. However, *Indigofera tinctoria* can be considered to be non-toxic following a single administration by the oral route on the basis of the data from a 13-week toxicity study in rats. In this study, no deaths were observed at dose levels of up to the limit dose level of 1000 mg/kg/day.

Ref: 11

#### 3.3.1.2 Acute dermal toxicity

##### Submissions I and II

No data submitted.

**Submission III**

No data submitted.

**3.3.1.3 Acute inhalation toxicity****Submissions I, II and III**

No data submitted.

**3.3.2 Irritation and corrosivity****3.3.2.1 Skin irritation****SCCS comments Submission I**

Indigo powder is considered as non-irritating to the skin in this test (OECD 404 (1992)).

**SCCS comments Submission II**

DA 060492, applied 'as is' under the conditions of this test, caused mild transient irritation to rabbit skin.

**Submission III**

Guideline:	OECD 439 (July 2015), ECVAM Standard Operating Procedure version 1.2: Episkin™ Skin irritation test 42 hours Determination of IL-1 $\alpha$ concentration in the culture medium (September 2005)
Test system:	Human reconstructed epidermis (Episkin™ tissues; 0.38 cm <sup>2</sup> )
Replicates:	Triplicate tissues for each item
Test substance:	E502657
Batch:	INP 161038
Purity:	/
Vehicle:	water
Concentration:	25% (liquid) and 100 % (solid)
Route:	dermal
Exposure:	Single application, 10 $\mu$ l (25% concentration) and 11 mg $\pm$ 1 mg (100% concentration)
Exposure duration:	15 minutes
Post-treatment incubation time:	42 hours
Negative control:	Dulbecco's Phosphate-Buffered Saline (D-PBS)
Positive control:	Sodium Dodecyl Sulphate (SDS) at a 5% (w/v) aqueous solution
Direct interaction with MTT:	Positive
Colouring potential test item:	Positive
GLP:	Yes
Study period:	6. March 2017 – 2. May 2017

A solubility test was performed prior to the preliminary tests in order to evaluate the solubility of the test item in water at the preselected concentration (i.e. 25% (w/v)). The solubility of the test item in water was evaluated by visual inspection.

Both undiluted and diluted *Indigofera tinctoria* at 25% were evaluated on 3 different batches of reconstructed human epidermis model. *Indigofera tinctoria*, the negative control (D-PBS), and the positive control (5% aqueous solution of Sodium Dodecyl Sulfate) were

1 tested in triplicate. One additional negative control (which followed the same treatment as  
2 the negative control, except the MTT incubation period) was added.

3 As the neat test item and the test item dilution were found to have both direct MTT  
4 reduction and colouring potential in the preliminary test, a third set of controls for non-  
5 specific colour in killed tissues was required. In this additional control, the test item (at both  
6 concentrations) was applied to two water-killed tissues and compared to two untreated  
7 water-killed tissues, which undergo the entire testing procedure but were incubated with  
8 medium instead of MTT solution during the MTT incubation step.

9  
10 10 mg +/- 2 mg of neat *Indigofera tinctoria* and 10 µL of the 25% (w/v) dilution in water  
11 and different controls were applied onto the epidermis using a positive displacement  
12 pipette. After a 15-minute treatment period (13 minutes for the neat test item) at room  
13 temperature, tissues were rinsed with D-PBS, and then epidermis were transferred in 2  
14 ml/well of fresh maintenance medium and incubated for 42 hours +/- 1 hour at 37°C.

15 The fact that the test item exhibits tissue colouring potential and an ability to directly  
16 interact with MTT was reflected in the performed calculations. The percentage of OD due to  
17 non-specific MTT reduction (NSMTT) as well as the non-specific OD due to the residual  
18 chemical colour (NSC<sub>living</sub> and NSC<sub>killed</sub>) were calculated. These allowed to calculate the true  
19 relative mean viability of the tissues treated with *Indigofera tinctoria*.

20 In addition, the concentration of the inflammatory mediator IL-1α was evaluated in the  
21 culture medium retained following the 42-hour recovery period. This quantification, based  
22 on an ELISA assay, was performed because the mean relative viability of the test item-  
23 treated tissues was > 50% following the MTT reduction assay.

24  
25 The study authors consider the study valid. The true mean viability value for *Indigofera*  
26 *tinctoria* at the concentrations of 100% and 25% w/v in water was 77% and 70%, with a  
27 mean IL-1α concentration of 9.8 and 9 pg/mL, respectively.

28  
29 The study authors conclude that, under the conditions of this study, *Indigofera tinctoria* at  
30 100% and at 25% w/v in water is potentially non-irritating.

31 Ref: 12

### 32 33 **SCCS overall conclusion on skin irritation**

34 Based on all available data from Submissions I-III, the SCCS considers *Indigofera tinctoria*,  
35 in the form as a dispersion or powder, to be non-irritating to the skin.

### 36 37 38 3.3.2.2 Mucous membrane irritation / eye irritation

#### 39 40 **SCCS comments Submission I**

41 The tested material induced significant damage to the rabbit eye and is considered to be  
42 irritating to the eye.

#### 43 44 **SCCS comments Submission II**

45 DA 060492 is considered to be irritating to the eye.

#### 46 47 **Submission III**

##### 48 49 *Study number 1*

50  
51 Guideline/method: OECD 437 (July 2013)  
52 GLP: Yes  
53 Test system: Corneas obtained from freshly slaughtered calves  
54 Replicates: Triplicate tissues  
55 Test substance: E502657 (100% *Indigofera tinctoria* Leaf powder)  
56 Test item: 20% (w/w) in 0.9% (w/v) NaCl in water  
57 Batch: INP 161038

---

1 Vehicle: 0.9% (w/v) NaCl in water  
2 Dose applied: 750 ± 8 µL  
3 Negative control: 0.9% (w/v) NaCl in water  
4 Positive control: 20% (w/w) imidazole solution in 0.9% (w/v) NaCl in water  
5 Exposure: Single application  
6 Exposure duration: 4 hours ± 10 min  
7 Study period: 11. June 2015 – 22. March 2017  
8

9 Bovine eyes (from cattle less than 12 months old) were collected at slaughterhouses and  
10 prepared within 4 hours of collection. Eyes that were too big or were presenting defects  
11 were rejected. After the pre-incubation and equilibration period of the corneas at 32 ± 1 C  
12 for 1h ± 10 minutes, 750 ± 8 µL of the test item *Indigofera tinctoria* (category: solid non  
13 surfactant) diluted at 20% (w/w) in NaCl 0.9% and controls were applied onto the corneas.  
14 The treatment period of 4 hours ± 10 minutes was followed by a 3 x rinsing step and visual  
15 examination of rinsing efficiency. Then, the corneal opacity and permeability were  
16 measured. Corneas were incubated with 0.5% fluorescein solution for 90 ± 5 minutes at 32  
17 ± 1 C; corneal permeability was performed by measuring optical density at 490 nm.  
18

19 The IVIS score obtained for *Indigofera tinctoria* diluted at 20% (w/w) in NaCl 0.9% after  
20 4-hour contact was 31.2±9.9. These scores, specifically the opacity, were probably  
21 overestimated as the corneas were coloured in a very light green by the test item.  
22

23 The study authors conclude that, under the conditions of this study, no conclusion can be  
24 drawn regarding the acute ocular irritation potential of *Indigofera tinctoria* diluted at 20%  
25 (w/w).  
26

Ref: 13

#### 27

#### 28 *Study number 2*

#### 29

30 Guideline/method: No  
31 GLP: Yes  
32 Test system: Corneas obtained from freshly slaughtered calves  
33 Replicates: Triplicate tissues  
34 Test substance: E502657  
35 Test item: 25% (w/w) in distilled water  
36 Batch: INP 161038  
37 Vehicle: Distilled water  
38 Dose applied: 750 ± 8 µL  
39 Negative control: Nutritive medium  
40 Positive control: 0.5% (w/w) cetyl trimethylammonium bromide (CTAB) in water  
41 Exposure duration: 10 and 30 minutes  
42 Study period: 23 December 2014 – 2. March 2017  
43

44 The test item *Indigofera tinctoria* at the concentration of 25% (w/w) in water was applied  
45 onto the cornea. The test item remained in contact with the isolated cornea for 10 ± 1  
46 minutes and 30 ± 5 minutes. At the end of the contact period, the corneas were rinsed and  
47 prepared for measurement of opacification (changes in light transmission) and permeability  
48 (evaluation of transfer of fluorescein through the cornea by measuring the optical density of  
49 the media in the ocular posterior compartment). The corneal score, which is the  
50 combination of opacification and permeability, was then calculated. Negative (nutritive  
51 medium) and positive control substances (hexadecyl trimethylammonium bromide at 0.5%  
52 in water) were tested according to the same experimental conditions.

53 The following validity criteria were applied in the study:

- 54 - initial opacity of the corneas: between 0 and 10
- 55 - O.D. of the negative control (nutritive medium) corneas: lower than 0.100
- 56 - O.D. of the fluorescein solution to 5 µg/mL: between 0.850 and 0.940
- 57 - score CTAB to 0.5%:

- 30 minutes: between 85.0 and 105.0
- 10 minutes: between 25.0 and 40.0.

The study fulfilled the validity criteria stated in the study report.

The score obtained for *Indigofera tinctoria* at the concentration of 25% (w/w) in water after 10- and 30-minutes contact was  $9.5 \pm 0.6$  and  $10.7 \pm 0.5$ , respectively; indicating classification as moderately irritant. However, the study authors state that the score and classification are given as a rough guide since the corneas were coloured lightly green and the opacity probably has been overestimated.

The study authors conclude that, under the conditions of this study, no conclusion can be given for the test item diluted at 25% (w/w) in distilled water.

Ref: 14

### SCCS comments Submission III

The applicants provided two new BCOP studies, one following the OECD guideline and one according to an in-house protocol. The exposure time of 10 to 30 minutes is too short compared to 4 hours recommended in OECD guideline. In both studies, colouring of the cornea occurred, indicating potential interference with the opacity and permeability measurement endpoints, which may lead to false estimates of the eye irritation potential. SCCS agrees with the study authors that both BCOP tests are inconclusive.

SCCS notes that in ECHA C&L inventory *Indigofera tinctoria*, ext. (extractives and their physically modified derivatives such as tinctures, concretes, absolutes, essential oils, oleoresins, terpenes, terpene-free fractions, distillates, residues, etc., obtained from *Indigofera tinctoria*, Leguminosae) with CAS 84775-63-3, in liquid form is self-classified by notifiers as eye irritant 2, H319: Causes serious eye irritation.

Ref: 15

### SCCS overall conclusion on eye irritation

Based on animal eye irritation studies from the previous submissions, the SCCS considers *Indigofera tinctoria* to be irritating to the eye. It should however be noted that since *Indigofera tinctoria* is a dispersion, mechanical damage to the eye may have been caused by the leaf powder.

## 3.3.3 Skin sensitisation

### SCCS comments Submission I

Indigo powder is classified as a sensitizer following skin contact in a maximisation test. *Indigofera tinctoria* powder can be considered as non-sensitising following skin contact in a Buehler Test.

### SCCS comments Submission II

Two Magnusson & Kligman studies show that DA 060492 is a contact allergen in this model and may be considered a strong contact allergen.

### Submission III

#### Local Lymph Node Assay (LLNA)

Guideline/method: OECD 429 (July 2010)  
GLP: Yes  
Test system: Local Lymph Node Assay (LLNA)  
Species/strain: Female mice, CBA/JRj, 8 weeks old

---

1	Group size:	2 (preliminary test) 4 per dose group (main test)
2	Test substance:	E213339
3	Batch:	SM/KS/24/8kGy/2
4	Vehicles:	Dimethyl sulfoxide (DMSO), 100% (w/v)
5		Acetone/olive oil (AOO), 4:1 (v/v)
6	Concentration:	Preliminary test: 10% (w/v) in DMSO
7		Main test: 0.5%, 1%, 2.5%, 5% and 10% (w/v) in DMSO
8	Route:	Application to the dorsal surface of both ears on days 1, 2 and 3
9	Positive control:	25% alpha-hexylcinnamaldehyde (HCA) in AOO
10	Negative control no. 1:	DMSO, 100% (W/v)
11	Negative control no. 2:	AOO, 4:1 (v/v)
12	Study period:	26. November 2012 – 26. December 2013 (in life phase ended
13		February 2013)

14  
15 Test material E213339 batch SM/KS/24/8kGy/2 (100% pure) was used in this study.  
16 Test concentrations used in the main study were selected based on a pre-screen test, in  
17 which 10% w/v of E213339 was considered as the maximum suitable test concentration.  
18 Four female CBA/J mice per group were used in the main study.

19  
20 Animals were treated with test solutions (25 µL per ear) at the concentrations of 0.5%, 1%,  
21 2.5%, 5% and 10% w/v in DMSO for three consecutive days by topical application on the  
22 dorsum of both ears. Negative control group received the vehicle alone (DMSO). Since a  
23 positive control groups was treated with HCA in AOO, a concurrent vehicle control group  
24 was treated with AOO alone. After 2 days of resting, all animals received a single  
25 intravenous injection of tritiated methyl thymidine (<sup>3</sup>H-TdR). After five hours, the draining  
26 auricular lymph nodes were excised and pooled per group to assess the proliferation of  
27 lymph node cells by measuring the incorporation of <sup>3</sup>H-TdR. The values obtained were used  
28 to calculate stimulation indices (SI). The irritant potential of the test item was assessed by  
29 measuring ear thickness on days 0, 2 and 5.

30  
31 No mortality or significant body weight losses (related to controls) or clinical signs of toxicity  
32 were observed in any of the treated groups. No erythema was induced by the test item.  
33 Slight ear thickness increase (+12.7%) was induced by the test item at a 10%  
34 concentration. As these ear thickness increases did not reach +25% on day 6 compared to  
35 day 1, they were not considered as excessive local irritation. Cell viability indexes were  
36 considered satisfactory in all groups. Calculated SI values were 0.9, 1.1, 1.5, 1.9 and 2.3  
37 for the test concentrations of 0.5%, 1%, 2.5%, 5%, and 10%, respectively. The SI value  
38 for positive control was 11.4.

39  
40 Under the conditions of this study, *Indigofera tinctoria* did not induce delayed contact  
41 hypersensitivity and was therefore considered to be devoid of sensitising potential. Based  
42 on these results, no EC3 value was calculated.

43 Ref: 8

#### 44 **SCCS comments Submission III**

45 Under the conditions of this study, *Indigofera tinctoria* was negative in the LLNA. SCCS  
46 notes that there is a dose-dependent increase in lymphocyte proliferation and that at the  
47 highest concentration tested (10%) a 2.3 fold increase was induced. This increase may be  
48 indicative for a sensitising potential at higher concentrations. It was, however, not possible  
49 to test *Indigofera tinctoria* at higher doses, because at 25% excessive local irritation in the  
50 prescreen test was noted.

51 Previous results of two independent Guinea pig maximisation tests showed that *Indigofera*  
52 *tinctoria* clearly induced contact allergy (Submission II, SCCS/1439/11). The Buehler test  
53 was negative, but erythema may be masked by the green skin staining caused by the test  
54 chemical. Hence taken all data together, a weak skin sensitising potential can not be  
55 excluded.

56

**3.3.4 Toxicokinetics****3.3.4.1 Dermal / percutaneous absorption****Submission I**

No data submitted.

**SCCS comments Submission II**

These were well performed experiments. Therefore, the mean+1SD may be used in calculating the MOS (1.34 µg/cm<sup>2</sup> or 0.85% of the applied dose of Indoxy β-D-glucoside).

**Submission III**

No data submitted

**3.3.4.2 Other studies on toxicokinetics**

/

**3.3.5 Repeated dose toxicity****3.3.5.1 Repeated dose (28 days) oral / dermal / inhalation toxicity****Submissions I, II, III**

No data submitted.

**3.3.5.2 Sub-chronic (90 days) oral / dermal / inhalation toxicity****Submissions I and II**

No data submitted.

**Submission III**

Guideline: OECD 408

Species/strain: Rat (*Rattus norvegicus*)/Wistar Hannover

Group size: 10 /sex/group

Test substance: E213339 (natural complex substances)

Batch: SM/KS/24/8kGy/2

Purity: 100% *Indigofera tinctoria* plant powder

Vehicle: Deionized water

Dose levels: 0, 30, 100, 300 or 1000 mg/kg bw/day

Dose volume: 10 mL/kg bw

Route: Oral

Administration: Gavage

Duration: 90 days

GLP: In compliance

Study period: 14. November 2012 – 22. April 2014 (in life phase ended February 2013)

The test material E213339 (natural complex substances) batch SM/KS/24/8kGy/2 (100% *Indigofera tinctoria* plant powder) was used in this study. Fifty (50) Wistar rats per sex were used in this study. The subchronic toxicity of *Indigofera tinctoria* was investigated in Wistar rats (10/sex/group) after daily oral gavage at 0, 30, 100, 300 or 1000 mg/kg/day in water (10 mL/kg) for 13 weeks. Evaluations and measurements included mortality checks, daily clinical observations, weekly body weight and food intake, ophthalmoscopy prior to dosing and at the end of the treatment period, neurotoxicological evaluation during week 12,

1 haematology, blood clinical chemistry and urinalysis (week 13). At the end of treatment  
2 period, surviving animals were killed and subjected to macroscopic examination; selected  
3 organs were weighed and a wide range of organs/tissues were preserved. Microscopic  
4 examination was performed for specified tissues/organs from control and high-dose rats  
5 killed at the end of the dosing period, as well as for any gross anomaly.  
6

7 The test item did not induce any relevant treatment-related changes with respect to  
8 survival, clinical signs, ophthalmological examinations as well as haematology, coagulation,  
9 and clinical chemistry parameters evaluated. No test item-related changes were detected  
10 regarding absolute and relative organ weights, gross and microscopic examination. No  
11 toxicologically significant test item-related neurological abnormalities were observed. There  
12 were no test item-related changes in body weights, body weight gain and food consumption  
13 at any of the dose levels.  
14

15 The only findings consisted of some changes in urinary parameters observed in females at  
16 300 and 1000 mg/kg/day that were collectively indicative of urinary concentration. This  
17 higher urine concentration is also probably responsible for the associated higher incidence of  
18 detection of proteins in females at the same dose levels. These effects, which relationship to  
19 treatment remains doubtful in the absence of similar changes in males, were not considered  
20 to be adverse in the absence of any associated biological, histopathological or kidney weight  
21 changes.

22 A higher incidence of presence of urinary ketone bodies was observed in the high dose in  
23 males and at 300 and 1000 mg/kg in females. The ketone values in the urine were of  
24 minimal degree. Ketonuria is not generally an indicator of impaired renal function but is  
25 rather related to a deficiency in carbohydrate metabolism, whereas there were no  
26 associated biochemical or pathological changes in this study. False-positive reactions with  
27 the detection of urinary ketone bodies is not uncommon in rat toxicity studies, specifically  
28 with indole chemicals oxidised to quinones known to produce such false positive reactions.  
29 Since the test item contains the indole compound "Indican", it is highly likely that the  
30 positive reactions observed are related to the urinary elimination of the test item *Indigofera*  
31 *tinctoria*. Based on all the above, these minor isolated findings were considered of no  
32 toxicological relevance.

33 Thus, under the conditions of the study, the NOAEL (No Observed Adverse Effect Level) of  
34 this 90-day oral toxicity study on *Indigofera tinctoria* was 1000 mg/kg/day in Wistar rats.

35 Ref: 11  
36

### 37 3.3.5.3 Chronic (> 12 months) toxicity

#### 38 **Submissions I, II and III**

39 No data submitted.  
40  
41  
42

### 43 **3.3.6 Reproductive toxicity**

#### 44 **Submissions I, II and III**

45 No data submitted.  
46  
47  
48

#### 49 3.3.6.1 Fertility and reproduction toxicity

#### 50 **Submissions I, II and III**

51 No data submitted.  
52  
53  
54



### 3.3.6.2 Developmental Toxicity

#### Submissions I and II

No data submitted.

#### Submission III

Guideline: OECD 414  
Species/strain: Rat (*Rattus norvegicus*)/Wistar Hannover  
Group size: 25 pregnant female rats/group (a total of 125 rats)  
Test substance: E213339 (natural complex substances)  
Batch: SM/KS/24/8kGy/2  
Purity: 100% *Indigofera tinctoria* plant powder  
Vehicle: Deionized water  
Dose levels: 0, 30, 100, 300 and 1000 mg/kg bw/day on GDs 6-19  
Dose volume: 10 mL/kg bw  
Route: Oral gavage  
Exposure period: From gestation day 6 to gestation day 19  
GLP: In compliance  
Study period: 4. January 2013 – 21. November 2014 (in life phase ended February 2013)

The test material E213339 (natural complex substances) batch SM/KS/24/8kGy/2 (100% *Indigofera tinctoria* plant powder) was used in this study. One hundred twenty-five (125) mated female Wistar rats were used. The potential effects of *Indigofera tinctoria* on pregnant rats and embryo-foetal development were evaluated through daily oral gavage in which mated Wistar female rats (25/group) were dosed at 0, 30, 100, 300 or 1000 mg/kg/day during the sensitive period of organogenesis from gestation day 6 to day 19 [the day of mating was designated as Gestation Day 0 (GD 0)]. The test item was dissolved in deionized water and given at 10 mL/kg. Maternal evaluations and measurements included daily clinical signs and body weight/food intake measured at designated intervals. The dams were killed on GD 20 and subjected to macroscopic examination. Usual litter parameters were recorded and foetuses were sexed, weighed and submitted to external examination. About one half of the foetuses were also examined for soft tissue anomalies, and remaining foetuses were examined for skeletal anomalies.

The administration of *Indigofera tinctoria* to pregnant female Wistar rats over the organogenesis period produced no mortality or gross necropsy findings. No statistically or biologically significant differences were observed in mean body weight, body weight gain, and corrected body weight gain and food intake when compared to controls. No changes in maternal parameters were noted in any group.

There were no fetal external and visceral findings attributed to the administration of the test item. Slight fetal skeletal malformations were observed at all the doses except the high dose of 1000 mg/kg. Since these changes were of moderate magnitude with no dose-response, they were not considered to be treatment-related. Even though some delayed skeletal ossification and/or incomplete ossification in the high-dose groups showed a statistically significant increase, these changes were isolated, of minimal to slight magnitude, and with incidences that overall remained within the historical control range. Therefore, they were considered as not related to the test item.

On the basis of the results obtained in the present study, the No Observed Adverse Effect Level (NOAEL) for maternal and developmental toxicity of *Indigofera tinctoria* was set at 1000 mg/kg/day. *Indigofera tinctoria* was considered to have no teratogenic potential.

Ref: 16

**SCCS Comments Submission III**

The SCCS has noted the bell-shaped dose response curve regarding the delay of ossification, which may be considered a transitory morphological alteration rather than a malformation. The SCCS considers that such a phenomenon is unlikely to be associated with the treatment. Nevertheless, the SCCS has considered the lowest dose at which the effects on the litter were seen (30 mg/kg/day) as LOAEL and this value has been used for calculating the MoS.

**3.3.7 Mutagenicity / genotoxicity****3.3.7.1 Mutagenicity / genotoxicity *in vitro*****Overall SCCS comments on mutagenicity/genotoxicity taken from Submission I**

The test item, as leaves powder (water extract) derived from the plant Indigo, has been tested on bacterial and mammalian cells *in vitro* for the induction of gene mutations, in mammalian cells *in vitro* for the induction of chromosome aberrations and on mice *in vivo* for the induction of numerical/structural chromosome aberrations.

The test item (ethanol extract) has been found strongly positive for the induction of gene mutations in bacterial cells. All the studies are inadequate because there is no characterisation of the material used as test item. No conclusion can be drawn about the potential mutagenicity/genotoxicity of the test item.

**Overall SCCS comments on mutagenicity/genotoxicity taken from Submission II**

Overall, the genotoxicity of *Indigofera tinctoria* is sufficiently investigated in valid genotoxicity tests for the 3 endpoints of genotoxicity: gene mutations, chromosome aberrations and aneuploidy. Under *in vitro* conditions, *Indigofera tinctoria* did not generally induce gene mutations in bacteria nor in mammalian cells. In one gene mutation test in bacteria with limited value due to a bad performance of the test, an induction of the number of revertants was observed. This positive finding was considered not biologically relevant. *Indigofera tinctoria* induced an increase in the number of cells with chromosome aberrations in one chromosome aberration test with limited value whereas in a well-performed test it was not genotoxic.

The positive finding in the single *in vitro* chromosome aberration test was not confirmed in a well-performed *in vivo* experiment. *Indigofera tinctoria* exposure of mice did not result in an increase in erythrocytes with micronuclei.

Consequently, based on the present reports, *Indigofera tinctoria* can be considered to have no *in vivo* genotoxic potential and additional tests are unnecessary.

**Submission III****Bacterial Reverse Mutation Test**

Guideline: OECD 471  
Test system: Salmonella typhimurium strains TA98, TA100, TA1535, TA1537, TA102  
Replicates: Two experiments, triplicate plates  
Test substance: E213339  
Batch: SM/KS/24/8kGy/2 (purity: composition was stated as 100% of *Indigofera tinctoria* plant powder)  
Concentrations: Experiment 1 – Plate incorporation test:  
±S9-mix: all *S. typhimurium* strains: 0, 5, 15.81, 50, 158.1, 500, 1581 and 5000 µg/plate

1  
2 Experiment 2  
3  $\pm$ S9-mix pre-incubation test: all S. strains: 0, 78.13, 156.3, 312.5,  
4 625, 1250, 2500, 5000  $\mu$ g/plate  
5 Additional plate incorporation test for TA102 S. strain +S9 mix: 0,  
6 78.13, 156.3, 312.5, 625, 1250, 2500, 5000  $\mu$ g/plate  
7 Vehicles: Dimethylformamide, DMF (stock suspension at 100 mg/mL); volume  
8 additions for the Experiment 2 pre-incubation treatments were  
9 reduced to 0.05 mL  
10 Positive Controls: -S9 mix: 2-nitrofluorene (2NF): 5  $\mu$ g/plate for TA98; Sodium azide  
11 ( $\text{NaN}_3$ ): 2  $\mu$ g/plate for TA100, TA1535; 9-Aminoacridine (AAC): 50  
12  $\mu$ g/plate for TA1537; Mitomycin C (MMC): 0.2  $\mu$ g/plate for TA102  
13 +S9 mix: Benzo[a]pyrene (B[a]P): 10  $\mu$ g/plate for TA98; 2-  
14 Aminoanthracene (AAN): 5  $\mu$ g/plate for TA100, TA1535 and TA1537,  
15 or 20  $\mu$ g/plate for TA102  
16 Negative controls: Vehicle control  
17 GLP: In compliance  
18 Study period: 09 Nov 2012 – 25 April 2013  
19

20 E213339 was tested for mutagenicity in the reverse mutation assay with and without  
21 metabolic activation in *S. typhimurium* strains TA1535, TA1537, TA98, TA100 and TA102,  
22 using both the Ames plate incorporation and pre-incubation methods at up to seven dose  
23 levels, in triplicate, in two separate experiments, both with and without the addition of a rat  
24 liver homogenate metabolising system (induced with Aroclor 1254, 10% liver S9 in standard  
25 co-factors).  
26

27 Experiment 1 treatments of all the tester strains were performed in the absence and in the  
28 presence of S9-mix, using final concentrations of E213339 at 5, 15.81, 50, 158.1, 500,  
29 1581 and 5000  $\mu$ g/plate, plus negative (vehicle) and positive controls. Following these  
30 treatments, no evidence of toxicity was observed. Experiment 2 treatments of all the tester  
31 strains were performed in the absence and in the presence of S9-mix. The maximum test  
32 concentration of 5000  $\mu$ g/plate was retained for all strains. Narrowed concentration intervals  
33 were employed covering the range 78.13 – 5000  $\mu$ g/plate. In addition, all treatments in the  
34 presence of S9-mix were further modified by the inclusion of a pre-incubation step. An  
35 additional plate incorporation treatment of strain TA102 in the presence of S9-mix was  
36 included in order to assess the reproducibility of results from Experiment 1. Following these  
37 treatments, no evidence of toxicity was observed.

38 Precipitation, in the form of suspension particles, was observed on the test plates at  
39 concentrations of 1581  $\mu$ g/plate and above in Experiment 1 and from 312.5  $\mu$ g/plate and  
40 above in Experiment 2.

41 The positive control chemicals all induced increases in revertant numbers of  $\geq 2.0$ -fold (in  
42 strains TA98, TA100 or TA102) or  $\geq 3.0$ -fold (in strains TA1535 or TA1537) in the concurrent  
43 vehicle control, confirming discrimination between different strains, and an active S-9  
44 preparation.  
45

46 Following Experiment 1 treatments of strain TA100 in the absence of S-9 and strain TA102  
47 in the absence and presence of S9-mix, increases in revertant numbers were observed that  
48 were statistically significant when the data were analysed at the 1% level using Dunnett's  
49 test. The increases observed were small in magnitude, did not display a clear concentration  
50 relationship and were not reproduced in a subsequent experiment. These increases are  
51 considered therefore to be chance occurrences and not indicative of mutagenic activity. No  
52 other increases in revertant numbers were observed that were statistically significant when  
53 the data were analysed at the 1% level using Dunnett's test.  
54

55 It was concluded by the authors of the study that E213339 did not induce mutation in five  
56 histidine-requiring strains (TA98, TA100, TA1535, TA1537 and TA102) of *Salmonella*  
57 *typhimurium* when tested under the conditions of this study. These conditions included

1 treatments at concentrations up to 5000 µg/plate (the maximum recommended  
2 concentration according to current regulatory guidelines), in the absence and in the  
3 presence of a rat liver metabolic activation system (S9-mix).

4 Ref: 17  
5

#### 6 **SCCS comments**

7 SCCS agrees that the results of the study indicate no mutagenic effect of *Indigofera*  
8 *tinctoria* in the absence or presence of S9 mix in all bacterial strains used. The SCCS noted  
9 that in Experiment 1, C170 was shown to increase the revertant number in three strains of  
10 *S. typhimurium* (TA100, -S9-mix, TA1537, +S9-mix and TA102, both ±S9-mix) at several  
11 concentrations, however the increases were not greater than 2 fold compared to the control  
12 values and the results were not reproducible in Experiment 2.  
13

#### 14 **Mammalian Cell Gene Mutation Test in Mouse Lymphoma Cells (*Hprt* locus)**

15  
16  
17 Guideline: OECD 476 (the Microtitre<sup>R</sup> fluctuation technique)  
18 Test system: L5178Y mouse lymphoma cell line *tk*<sup>+/-</sup> (3.7.2C), (*hprt*) locus  
19 Replicates: Two independent experiments, each two parallel cultures  
20 Test substance: E213339  
21 Batch: SM/KS/24/8kGy/2 (purity: composition was stated as 100% of  
22 *Indigofera tinctoria* plant powder)  
23 Concentrations: Preliminary test (range-finder):  
24 ±S9 mix (3 h exposure) and -S9 mix (3 h exposure): 31.25,  
25 62.5, 125, 250, 500, 1000 µg/mL  
26  
27 Main test:  
28 Experiment I:  
29 +S9-mix (3 h exposure) and -S9-mix (3 h exposure): 10, 20,  
30 40, 60, 80, 90, 100, 110, 125, 250, 500, 1000 µg/mL  
31  
32 Experiment II:  
33 +S9-mix (3 h exposure) and -S9-mix (3 h exposure): 7.5, 15,  
34 30, 60, 90, 115, 125, 250, 500, 1000 µg/mL  
35 Vehicle: Dimethylformamide (DMF) (stock suspension at 100 mg/mL)  
36 Negative control: Culture medium and DMF diluted 100-fold in the treatment  
37 medium  
38 Positive controls: -S9-mix: 4-nitroquinoline 1-oxide (NQO), 0.15 and 0.2 µg/mL  
39 +S9-mix: benzo[a]pyrene (B[a]P), 2 and 3 µg/mL  
40 GLP: Yes  
41 Study period: 08 Nov 2012 – 29 April 2013  
42

43 The *in vitro* mammalian cell gene mutation assay was conducted to investigate the potential  
44 of C170 dissolved in DMF to induce gene mutations at the *hprt* locus of the L5178Y mouse  
45 lymphoma cell line. Prior to the main study, a preliminary toxicity test was performed on  
46 cell cultures using a 3-hour exposure time both with and without metabolic activation (S9,  
47 liver post mitochondrial supernatant of rats treated with Aroclor 1254). The dose range  
48 used was 31.25 to 1000 µg/mL (the maximum practicable concentration, limited by the  
49 solubility in the primary vehicle). The test article was formulated as a doseable suspension  
50 in DMF, therefore all concentrations may be regarded as nominal.  
51

52 The following main study was performed in two independent experiments, using two parallel  
53 cultures each. In the first experiment of the main study, C170 treatments were performed  
54 for 3 h in duplicate (A + B) both with and without metabolic activation (S9-mix) at 12 dose  
55 levels of the test item (10 - 1000 µg/mL), vehicle and positive controls. In the second  
56 experiment of the main study, the dose range of the test item was 7.5 - 1000 µg/mL in the  
57 presence and absence of S9-mix.

1  
2 In the cytotoxicity **Range-Finder Experiment**, upon addition of the test article to the  
3 cultures, precipitate/undissolved test article was observed at the highest three  
4 concentrations tested in the absence and presence of S9-mix (250 to 1000 µg/mL).  
5 Following the 3 hour treatment incubation period, precipitate/undissolved test article was  
6 observed at the highest four concentrations in the absence and presence of S9-mix (125 to  
7 1000 µg/mL). The lowest concentration at which precipitate/undissolved test article was  
8 observed at the end of the treatment incubation period in the absence and presence of S9-  
9 mix was retained and higher concentrations were discarded. The highest concentration  
10 analysed (125 µg/mL) gave minimal toxicity, such that relative survival (RS) values were  
11 112% and 76% in the absence and presence of S9-mix, respectively.  
12

13 In **Experiment 1**, twelve concentrations, ranging from 10 to 1000 µg/mL, were tested in  
14 the absence and presence of S9-mix. No precipitate/undissolved test article was observed  
15 at the time of treatment but following the 3 hour treatment incubation period,  
16 precipitate/undissolved test article was observed at the highest three concentrations in the  
17 absence and presence of S9-mix (250 to 1000 µg/mL). The lowest concentration at which  
18 precipitate/undissolved test article was observed at the end of the treatment incubation  
19 period in the absence and presence of S9-mix was retained and higher concentrations were  
20 discarded. Seven days after treatment, concentrations of 10 and 80 µg/mL in the absence  
21 and presence of S9-mix were not selected as there were sufficient non-toxic concentrations.  
22 All other concentrations were selected in the absence and presence of S9-mix. The highest  
23 concentration analysed was 250 µg/mL, which gave 61% and 68% RS in the absence and  
24 presence of S9-mix, respectively.  
25

26 In **Experiment 2**, ten concentrations, ranging from 7.5 to 1000 µg/mL, were tested in the  
27 absence and presence of S9-mix. No precipitate/undissolved test article was observed at  
28 the time of treatment but following the 3 hour treatment incubation period,  
29 precipitate/undissolved test article was observed at the highest six concentrations in the  
30 absence of S9-mix (90 to 1000 µg/mL) and the highest four concentrations in the presence  
31 of S9-mix (125 to 1000 µg/mL). The lowest concentrations at which precipitate/undissolved  
32 test article was observed at the end of the treatment incubation period in the absence and  
33 presence of S9-mix were retained and higher concentrations were discarded. The highest  
34 concentrations analysed were 90 and 125 µg/mL, which gave 81% and 62% RS in the  
35 absence and presence of S9-mix, respectively.  
36

37 Negative (vehicle) and positive control treatments were included in each Mutation  
38 Experiment in the absence and presence of S9-mix. Mutant frequencies (MF) in vehicle  
39 control cultures fell within acceptable ranges and clear increases in mutation were induced  
40 by the positive control chemicals 4-nitroquinoline 1-oxide (without S9-mix) and  
41 benzo(a)pyrene (with S9-mix). Therefore the study was accepted as valid.  
42

43 In Experiments 1 and 2, no statistically significant increases in **mutant frequency** were  
44 observed following treatment with E213339 at any concentration tested in the absence and  
45 presence of S9-mix and there were no significant linear trends. It was, however, noted that  
46 a significant difference in MF was observed for the Untreated Control (UTC) compared to the  
47 vehicle control MF in Experiment 1 in the presence of S9-mix. However, as the UTC does  
48 not form part of the endpoint analysis and the vehicle control MF (5.34) was within three  
49 times the historical MF (5.75 at the time of Experiment 1) and therefore meets the  
50 acceptance criteria, this observation was considered to have had no adverse effect on the  
51 integrity of the experiment.  
52

53 *It is concluded that E213339 did not induce mutation at the hprt locus of L5178Y mouse*  
54 *lymphoma cells when tested up to the limit of solubility of the test article in culture medium*  
55 *in two independent experiments, in the absence and presence of a rat liver metabolic*  
56 *activation system (S9-mix).*  
57

**SCCS comments**

The SCCS agrees that the study indicates no mutagenic effect of *Indigofera tinctoria* in the *Hprt* locus in mouse lymphoma L5178Y cells.

The SCCS noted that in the study, rather low MF was observed for the positive control substance. The ratio C/H was 0.337-0.531 for NQO at 0.2 µg/mL, while for NQO at 0.1 µg/mL MF was generally similar to historical control (ratio C/H: 0.836-0.908).

***In vitro* Micronucleus Test in human lymphocytes**

Guideline: OECD 487 (2010)  
Species/strain: Cultured human peripheral blood lymphocytes from two male volunteers (pooled blood)  
Replicates: Duplicate cultures, one experiment  
Test substance: E213339  
Batch: SM/KS/24/8kGy/2 (purity: composition was stated as 100% *Indigofera tinctoria* plant powder)  
Concentrations: Preliminary test (range-finder):  
±S9 mix (3 h exposure + 21 h) and -S9 mix (24 h exposure): 3.628, 6.047, 10.08, 16.80, 27.99, 46.66, 77.76, 129.6, 216, 360, 600, 1000 µg/mL  
Exp1:  
±S9-mix (3 h exposure + 21 h): 175, 200, 300, 400, 600 µg/mL  
-S9-mix (24 h exposure): 150, 175, 200, 300, 400, 600 µg/mL  
Solvent/negative control: Culture medium and dimethylformamide (DMF)  
Positive Controls: -S9-mix: Mitomycin C (MMC, 0.6 and 0.8 µg/mL), Vinblastine (VIN, 0.02, 0.03 and 0.04 µg/mL)  
+S9-mix: Cyclophosphamide (CPA, 6.25 and 12.5 µg/mL)  
Vehicle: DMF (stock suspension at 100 mg/mL)  
GLP: In compliance  
Study period: 09 Nov 2012 – 24 April, 2013

In an *in vitro* micronucleus assay, C170 was tested using duplicate human lymphocyte cultures prepared from the pooled blood of two male donors in one experiment for clastogenicity and aneugenicity assessment. The maximum concentrations analysed were determined following a preliminary cytotoxicity experiment. Cytotoxicity was assessed as reduction in the replication index (RI). Suitable maximum concentrations for analysis were selected.

The test article was formulated as a doseable suspension in dimethyl formamide (DMF), therefore all concentrations may be regarded as nominal. The highest concentrations analysed in the Micronucleus Experiment were limited by the appearance of precipitate and/or undissolved test article and were determined following a preliminary cytotoxicity Range-Finder Experiment.

Treatments were conducted 48 hours following mitogen stimulation with Phytohaemagglutinin (PHA). Cells were exposed to the test item in the vehicle DMF for 3 hours (followed by 21 hours recovery) in the absence and the presence of a mammalian metabolic activation system (S9-mix from the liver of Aroclor 1254 induced rats. In addition, cells were exposed for 24 hours (equivalent to approximately 1.5 to 2 times the average generation time of cultured lymphocytes from the panel of donors used in this laboratory) in the absence of S9-mix.

Negative and positive controls were in accordance with the OECD guideline.

All cultures were sampled 24 hours after the beginning of treatment (*i.e.* 72 hours after culture initiation). A total of 1000 binucleate cells from each culture (2000 cells/concentration) was analysed for micronuclei.

1  
2 Treatment of cells with E213339 in the absence and presence of S-9 resulted in frequencies  
3 of MNBN cells that were similar to (and not significantly higher than) those observed in  
4 concurrent vehicle controls at all concentrations analysed under all treatment conditions.  
5 The MNBN cell frequency of all E213339 treated cultures fell within the normal ranges.  
6

7 It is concluded that E213339 did not induce micronuclei in cultured human peripheral blood  
8 lymphocytes when tested up to precipitating concentrations for 3 hours in the absence and  
9 presence of a rat liver metabolic activation system (S9-mix) and for 24 hours in the absence  
10 of S9-mix.

Ref: 19

**SCCS comments**

11  
12 The SCCS agrees that the study indicates no mutagenic effect of *Indigofera tinctoria* in the  
13 micronucleus test in human lymphocytes.

14 The SCCS noted that the frequency of MNBN cells in vehicle controls fell within the normal  
15 ranges with the exception of one culture following 24+0 hour treatment in the absence of  
16 S9-mix (1.7 vs observed range of 0.00-1.5, 95% reference range of 0.1-1.1 in historical  
17 control).  
18  
19

**3.3.7.2 Mutagenicity / genotoxicity *in vivo*****Submission III**

20  
21  
22 No additional data submitted.  
23  
24  
25

**Overall SCCS comments on *in vitro* and *in vivo* mutagenicity/genotoxicity based on Submission I, II and III**

26 The genotoxicity of *Indigofera tinctoria* was investigated with valid *in vitro* genotoxicity tests  
27 for the three endpoints of genotoxicity: gene mutations (in both bacterial and mammalian  
28 test systems), chromosome aberrations and aneuploidy (in the micronucleus test), with  
29 negative results. In an *in vivo* experiment, *Indigofera tinctoria* exposure of mice did not  
30 result in an increase in erythrocytes with micronuclei.  
31

32 Based on the provided studies, *Indigofera tinctoria* can be considered to have no *in vivo*  
33 genotoxic potential.  
34  
35  
36

**3.3.8 Carcinogenicity****Submissions I, II and III**

37  
38  
39 No data submitted.  
40

**3.3.9 Photo-induced toxicity****3.3.9.1 Phototoxicity / photo-irritation and photosensitisation****Submissions I, II and III**

41  
42  
43  
44 No data submitted.  
45  
46  
47

**3.3.9.2 Photomutagenicity / photoclastogenicity****Submissions I, II and III**

48  
49  
50 No data submitted.  
51  
52

**3.3.10 Human data****Submissions I, II and III**

No data submitted.

**SCCS Comments on Submission III**

There are no published studies that show the existence of contact allergy induced by Indigo. Indirubin has anti-inflammatory anti-cell proliferative properties. It is currently under investigation as a topical treatment for skin diseases such as psoriasis.

Ref: 20-22

**3.3.11 Special investigations**

/

**3.3.12 Safety evaluation (including calculation of the MOS)****CALCULATION OF THE MARGIN OF SAFETY**

(on-head concentrations of up to 25%)

A LOAEL of 30 mg/kg bw/day derived from the developmental toxicity study is taken as a Point of Departure (PoD) for the MoS-calculations. Since the POD is based on a LOAEL, an assessment factor of 3 is added in the calculation of the MoS.

Absorption through the skin	A	=	1.34 µg/cm <sup>2</sup>
Skin Surface Area	SSA	=	580 cm <sup>2</sup>
Dermal absorption per treatment	SSA x A x 0.001	=	0.78 mg
Typical body weight of human	bw	=	60 kg
Systemic exposure dose (SED)	SSA x A x 0.001/bw	=	0.013 mg/kg
Lowest observed adverse effect level	LOAEL	=	30 mg/kg bw/d
NOAEL (Adjusted LOAEL)	NOAEL	=	10 mg/kg bw/d
Bioavailability 50%*	NOAEL <sub>sys</sub>	=	5 mg/kg bw/d

<b>Margin of Safety</b>	<b>NOAEL<sub>sys</sub>/SED</b>	<b>=</b>	<b>385</b>
-------------------------	--------------------------------	----------	------------

\* standard procedure according to the SCCS's Notes of Guidance for the testing of cosmetic ingredients and their safety evaluation.

**3.3.13 Discussion****Physicochemical properties**

The composition analysis refers only to 4% of the components for the test material E213339 that was used in the 2/3 of the studies conducted.

*Indigofera tinctoria* is a complex chemical mixture. All impurities should be chemically characterised and quantified based on the % area content calculated at λ<sub>max</sub> of the major components.

Heavy metal impurities such as lead must be kept below the acceptable limits. For heavy metal impurities > trace levels, the valence state of the ion and the salt form should be provided.



---

**Function and uses**

The ingredient *Indigofera tinctoria* is used in non-oxidative hair colouring products at a maximum on-head concentration of 25% (i.e. 100 g of *Indigofera tinctoria* mixed with 300 mL of hot water between 50°C and 100°C).

**Toxicological Evaluation****Acute toxicity**

No acute oral toxicity study was performed with *Indigofera tinctoria*. However, on the basis of the data from a 13-week toxicity study in rats, no deaths were observed at any dose level up to the limit dose level of 1000 mg/kg/day.

**Irritation and corrosivity**

Based on all available data from Submissions I-III, the SCCS considers *Indigofera tinctoria*, in the form as a dispersion or powder, to be non-irritating to the skin. Based on animal eye irritation studies from the previous submissions, the SCCS considers *Indigofera tinctoria* to be irritating to the eye. It should however be noted that since *Indigofera tinctoria* is a dispersion, mechanical damage to the eye may have been caused by the leaf powder. The SCCS notes that in ECHA C&L inventory *Indigofera tinctoria* extract in liquid form is self-classified by notifiers as eye irritant 2, H319: Causes serious eye irritation.

**Skin sensitisation**

Under the conditions of this study, *Indigofera tinctoria* was negative in the LLNA. The SCCS notes the highest dose tested (10%) induced a 2.3 fold increase in lymphocyte proliferation. This increase may be indicative for a sensitising potential at higher concentrations. It was, however, not possible to test *Indigofera tinctoria* at higher doses, because at 25% excessive local irritation in the pre-screen test was noted. Previous results of two independent Guinea pig maximisation tests showed that *Indigofera tinctoria* induced contact allergy (Submission II, SCCS/1439/11). Taking the data together, a weak skin-sensitising potential cannot be excluded. There are no indications from human data that *Indigofera tinctoria* causes allergic contact dermatitis.

**Toxicokinetics**

The mean+1SD is used in calculating the margin of safety (MOS), i.e. 1.34 µg/cm<sup>2</sup> or 0.85% of the applied dose of Indican.

**Repeated dose toxicity**

A NOAEL of the 90-day oral toxicity study on *Indigofera tinctoria* was 1000 mg/kg/day in rats.

**Reproductive toxicity**

The SCCS has noted the bell-shaped dose response curve regarding the delay of ossification, which may be considered a transitory morphological alteration rather than a malformation. The SCCS considers that such a phenomenon is unlikely to be associated with the treatment. Nevertheless, the SCCS has considered the lowest dose at which the effects on litter was seen (30 mg/kg/day) as LOAEL and this value has been used for calculating the MoS

**Mutagenicity / genotoxicity**

The genotoxicity of *Indigofera tinctoria* was investigated with valid *in vitro* genotoxicity tests for the three endpoints of genotoxicity: gene mutations (in both bacterial and mammalian test systems), chromosome aberrations and aneuploidy (in the micronucleus test), with negative results. In an *in vivo* experiment, *Indigofera tinctoria* exposure of mice did not result in an increase in erythrocytes with micronuclei. Based on the provided studies, *Indigofera tinctoria* can be considered to have no *in vivo* genotoxic potential.

1 **Carcinogenicity**

2 /

3  
4 **Photo-induced toxicity**

5 /

6  
7 **Human data**

8 There are no published studies that show the existence of contact allergy induced by Indigo.  
9 Indirubin has anti-inflammatory and anti-proliferative properties.

10  
11  
12 **Special investigation**

13 /

14  
15  
16 **4. CONCLUSION**

17  
18  
19 *1. In light of the data provided, does the SCCS consider Indigofera tinctoria (C170) safe*  
20 *when used in non-oxidative conditions hair colouring products at on-head concentrations*  
21 *of up to 25%?*

22  
23 In light of the data provided, the SCCS considers that *Indigofera tinctoria* is safe when  
24 used in non-oxidative condition hair colouring products as on-head concentrations of up  
25 to 25%.

26  
27  
28 *2. Does the SCCS have any further scientific concerns with regard to the use of Indigofera*  
29 *tinctoria (C170) in cosmetic products?*

30 A weak skin sensitisation potential cannot be excluded for *Indigofera tinctoria*.

31  
32  
33 **5. MINORITY OPINION**

34 /

---

## 6. REFERENCES

1. HQ Indigo. *Indigofera tinctoria*. Analytical file March 2018.
2. PubChem. Compound summary of Indigo. Downloaded 29. November 2019. Available at: <https://pubchem.ncbi.nlm.nih.gov/compound/10215#section=Names-and-Identifiers>
3. PubChem. Compound summary of Indirubin. Downloaded 29. November 2019. Available at: <https://pubchem.ncbi.nlm.nih.gov/compound/10177#section=Names-and-Identifiers>
4. Kancor.2017. Certificate of analysis lot KAN IN 25 KGY 1216 01.
5. Kancor.2017. Certificate of analysis lot KAN IN 25 KGY 1216 03.
6. *Indigo tinctoria*. Safety file for amended Submission IV May 2019.
7. Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (2017). Technically avoidable heavy metal contents in cosmetic products. J Consum Prot Food Saf;12:51-53.
8. Ferraz Menezes D (2013). Evaluation of Skin Sensitization Potential in the Mouse of E213339 using the Local Lymph Node Assay (LLNA). Bioagri Study No. 9050.470.036.12.
9. HQ Indigo. *Indigofera tinctoria*. Analytical file October 2017.
10. HQ Indigo. *Indigofera tinctoria*. Analytical file May 2019.
11. Rodriguez Gomez J (2014). Repeated Dose 13-Week Oral Toxicity Study with E213339 In Wistar Rats. Bioagri Study No. 9050.307.008.12.
12. Richez A. (2017). E502657. *In vitro* Skin Irritation on Episkin<sup>SM</sup> Reconstructed Human Epidermis. CiToxLab Study No. 44991 TIC.
13. Cannamela N (2017a). Ocular primary irritation B.C.O.P. – Study Performed on the Isolated Bovine Cornea. Measurement of the Bovine Corneal Opacity and Permeability (according to the OECD protocol n°437 of 26 July 2013). IEC Report No 170253RD
14. Cannamela N (2017b). Ocular primary irritation B.C.O.P. – Study Performed on the Isolated Bovine Cornea. Measurement of the Bovine Corneal Opacity and Permeability. IEC Report No 170252RD.
15. ECHA. Substance information. *Indigofera tinctoria*, ext. Downloaded 18. November 2019. Available at: <https://echa.europa.eu/substance-information/-/substanceinfo/100.076.237>.
16. Betancourt Martell (2014). Prenatal Developmental Oral Toxicity Study with E213339 In Wistar Rats. Bioagri Study No. 9050.314.008.12.
17. Mc Garry S (2013). E213339: Reverse Mutation in five histidine-requiring strains of *Salmonella typhimurium*. Covance Study No. 8275464.
18. Massip A-M (2013). E213339: Mutation at the *hprt* locus of Mouse Lymphoma L5178Y Cells (MLA) using the Microtitre<sup>®</sup> Fluctuation Technique. Covance Study No. 8275466.
19. Lloyd M (2013). E213339: Induction of Micronuclei in Cultured Human Peripheral Blood Lymphocytes. Covance Study No. 8275465.
20. Hsieh WL, Lin YK, Tsai CN, Wang TM, Chen TY, Pang JH. Indirubin, an acting component of indigo naturalis, inhibits EGFR activation and EGF-induced CDC25B gene expression in epidermal keratinocytes. J Dermatol Sci. 2012;67:140-146.
21. Lin YK, See LC, Huang YH, Chi CC, Hui RC. Comparison of Indirubin concentrations in indigo naturalis ointment for psoriasis treatment: a randomized, double-blind, dosage-controlled trial. Br J Dermatol. 2018;178:124-131.
22. Swan BC, Tam MM, Higgins CL, Nixon RL (2016) Allergic contact dermatitis to substitute hair dyes in a patient allergic to para-phenylenediamine: Pure henna, black tea and indigo powder. Australas J Dermatol. 57:219-21

1 **7. GLOSSARY TERMS**

2  
3 See SCCS/1564/15, 9th Revision of the SCCS Notes of Guidance for the Testing of Cosmetic  
4 Ingredients and their Safety Evaluation – from page 144

5  
6

7 **8. LIST OF ABBREVIATIONS**

8  
9 See SCCS/1564/15, 9th Revision of the SCCS Notes of Guidance for the Testing of Cosmetic  
10 Ingredients and their Safety Evaluation – from page 144.